Victrelis Disease Interactions
There is 1 disease interaction with Victrelis (boceprevir).
Boceprevir (applies to Victrelis) pancytopenia
Moderate Potential Hazard, Moderate plausibility.
Anemia, neutropenia and thrombocytopenia has been reported with the use of boceprevir. Boceprevir is always administered with peginterferon alfa and ribavirin which are also associated with pancytopenia. The addition of boceprevir has shown an additional decrease in hemoglobin and blood cell counts. Caution should be used in patients with preexisting anemia, neutropenia or thrombocytopenia. A complete blood count should be obtained pretreatment, and then during treatment at weeks 2, 4, 8, and 12. Patients should be monitored closely. Refer to the prescribing information for peginterferon alfa and ribavirin for additional information regarding dose reduction or discontinuation based on laboratory parameters. If ribavirin and peginterferon alfa need to be discontinued, boceprevir should be discontinued as well.
References
- (2011) "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation
Victrelis drug interactions
There are 452 drug interactions with Victrelis (boceprevir).
Victrelis alcohol/food interactions
There is 1 alcohol/food interaction with Victrelis (boceprevir).
More about Victrelis (boceprevir)
- Victrelis consumer information
- Check interactions
- Compare alternatives
- Reviews (3)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: protease inhibitors
- Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.